Chronic immune stimulation as a contributing cause of chronic disease in opiate addiction including multi-system ageing

Medical Hypotheses

Volumn 75, Issue 6, 2010, Pages 613-619

  Reece, Albert Stuart ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; DIAMORPHINE; METHADONE; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN PROTEIN; OPIATE; TOLL LIKE RECEPTOR;

ARTICLE; ATHEROSCLEROSIS; CHRONIC DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DEGENERATIVE DISEASE; DRUG RECEPTOR BINDING; HUMAN; HYPERGAMMAGLOBULINEMIA; IMMUNOSTIMULATION; LYMPHOCYTOSIS; MENTAL DISEASE; MONOCYTOSIS; OPIATE ADDICTION; PROTEIN BLOOD LEVEL; PROTEIN INDUCTION;

AGING; CHRONIC DISEASE; HUMANS; LYMPHOCYTE ACTIVATION; OPIOID-RELATED DISORDERS; TOLL-LIKE RECEPTORS;

EID: 77958461422     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2010.07.047     Document Type: Article

References (172)

1. Stein M.D. Medical consequences of substance abuse. Psychiatr Clin North Am 1999, 22:351-370.
2. Gottshcalk L.A., McGuire F.L., Heiser J.F., Dinovo E.C., Birch H. Drug abuse deaths in nine cities: A survey report. NIDA Research Monograph 1979, vol. 29:1-189. National Institutes of Health, Bethesda, Maryland, USA.
3. Burns L., Randall D., Hall W.D., Law M., Butler T., Bell J., et al. Opioid agonist pharmacotherapy in New South Wales from 1985 to 2006: patient characteristics and patterns and predictors of treatment retention. Addiction 2009, 104:1363-1372.
4. Darke S., Kaye S., Duflou J. Systemic disease among cases of fatal opioid toxicity. Addiction 2006, 101:1299-1305.
5. Cami J., Farre M. Drug addiction. N Engl J Med 2003, 349:975-986.
6. Isbell H., White W.M. Clinical characteristics of addictions. Am J Med 1953, 14:558-565.
7. Andresz V., Marcantoni N., Binder F., Velten M., Alt M., Weber J.C., et al. Puffy hand syndrome due to drug addiction: a case-control study of the pathogenesis. Addiction 2006, 101:1347-1351.
8. Goodman and gilman's the pharmacologic basis of therapeutics 2006, McGraw Hill, New York. 11th ed. L.L. Brunton, J.S. Lazo, K.L. Parker (Eds.).
9. Reece A.S. Evidence of accelerated ageing in clinical drug addiction from immune, hepatic and metabolic biomarkers. Immun Ageing 2007, 4:6-15.
10. Dyer K.R., White J.M. Patterns of symptom complaints in methadone maintenance patients. Addiction 1997, 92:1445-1455.
11. Lavie E., Fatseas M., Denis C., Auriacombe M. Benzodiazepine use among opiate-dependent subjects in buprenorphine maintenance treatment: correlates of use, abuse and dependence. Drug Alcohol Depend 2009, 99:338-344.
12. Darke S., Hall W., Ross M., Wodak A. Benzodiazepine use and HIV risk-taking behaviour among injecting drug users. Drug Alcohol Depend 1992, 31:31-36.
13. Peles E., Schreiber S., Naumovsky Y., Adelson M. Depression in methadone maintenance treatment patients: rate and risk factors. J Affect Disord 2007, 99:213-220.
14. Backmund M., Meyer K., Henkel C., Soyka M., Reimer J., Schutz C.G. Co-consumption of benzodiazepines in heroin users, methadone-substituted and codeine-substituted patients. J Addict Dis 2005, 24:17-29.
15. Weizman T., Gelkopf M., Melamed Y., Adelson M., Bleich A. Treatment of benzodiazepine dependence in methadone maintenance treatment patients: a comparison of two therapeutic modalities and the role of psychiatric comorbidity. Aust N Z J Psychiatry 2003, 37:458-463.
16. Hoge E.A., Brandstetter K., Moshier S., Pollack M.H., Wong K.K., Simon N.M. Broad spectrum of cytokine abnormalities in panic disorder and posttraumatic stress disorder. Depress Anxiety 2009, 26:447-455.
17. Blandino P., Barnum C.J., Solomon L.G., Larish Y., Lankow B.S., Deak T. Gene expression changes in the hypothalamus provide evidence for regionally-selective changes in IL-1 and microglial markers after acute stress. Brain Behav Immun 2009, 23:958-968.
18. Gosselin D., Rivest S. Role of IL-1 and TNF in the brain: twenty years of progress on a Dr. Jekyll/Mr. Hyde duality of the innate immune system. Brain Behav Immun 2007, 21:281-289.
19. Stewart J.C., Rand K.L., Muldoon M.F., Kamarck T.W. A prospective evaluation of the directionality of the depression-inflammation relationship. Brain Behav Immun 2009, 23:936-944.
20. Gimeno D., Kivimaki M., Brunner E.J., Elovainio M., De Vogli R., Steptoe A., et al. Associations of C-reactive protein and interleukin-6 with cognitive symptoms of depression: 12-year follow-up of the Whitehall II study. Psychol Med 2009, 39:413-423.
21. Howren M.B., Lamkin D.M., Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med 2009, 71:171-186.
22. Watkins L.R., Maier S.F. The pain of being sick: implications of immune-to-brain communication for understanding pain. Annu Rev Psychol 2000, 51:29-57.
23. Moraska A., Campisi J., Nguyen K.T., Maier S.F., Watkins L.R., Fleshner M. Elevated IL-1beta contributes to antibody suppression produced by stress. J Appl Physiol 2002, 93:207-215.
24. Hutchinson M.R., Bland S.T., Johnson K.W., Rice K.C., Maier S.F., Watkins L.R. Opioid-induced glial activation: mechanisms of activation and implications for opioid analgesia, dependence, and reward. ScientificWorldJournal 2007, 7:98-111.
25. Hutchinson MR, Ramos KM, Loram LC, Wieseler J, Sholar PW, Kearney JJ et al. Evidence for a role of heat shock protein-90 (HSP90) in TLR4 mediated pain enhancement in rats, Neuroscience 2009.
26. Hutchinson MR, Zhang Y, Shridhar M, Evans JH, Buchanan MM, Zhao TX et al. Evidence that opioids may have toll-like receptor 4 and MD-2 effects, Brain Behav Immun 2009.
27. Milligan E.D., Watkins L.R. Pathological and protective roles of glia in chronic pain. Nat Rev Neurosci 2009, 10:23-36.
28. Watkins LR, Hutchinson MR, Rice KC, Maier SF. The " Toll" of opioid-induced glial activation: improving the clinical efficacy of opioids by targeting glia, Trends Pharmacol Sci 2009.
29. Sadeghian S., Darvish S., Davoodi G., Salarifar M., Mahmoodian M., Fallah N., et al. The association of opium with coronary artery disease. Eur J Cardiovasc Prev Rehabil 2007, 14:715-717.
30. Fauci A.S., Braunwald E., Kapser D.L., Hauser S.L., Longo D.L., Jameson J.L., et al. Harrison's principles of internal medicine 2008, McGraw Hill, New York. 17th ed.
31. Mora S., Ridker P.M. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) - can C-reactive protein be used to target statin therapy in primary prevention?. Am J Cardiol 2006, 97:33A-41A.
32. Nissen S.E., Tuzcu E.M., Schoenhagen P., Crowe T., Sasiela W.J., Tsai J., et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005, 352:29-38.
33. Ray K.K., Cannon C.P., Cairns R., Morrow D.A., Rifai N., Kirtane A.J., et al. Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2005, 46:1417-1424.
34. Ridker P.M., Cannon C.P., Morrow D., Rifai N., Rose L.M., McCabe C.H., et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005, 352:20-28.
35. Ridker P.M., Rifai N., Clearfield M., Downs J.R., Weis S.E., Miles J.S., et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001, 344:1959-1965.
36. Ridker P.M., Rifai N., Rose L., Buring J.E., Cook N.R. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002, 347:1557-1565.
37. Ruckerl R., Peters A., Khuseyinova N., Andreani M., Koenig W., Meisinger C., et al. Determinants of the acute-phase protein C-reactive protein in myocardial infarction survivors: the role of comorbidities and environmental factors. Clin Chem 2009, 55:322-335.
38. Albert M.A., Danielson E., Rifai N., Ridker P.M. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001, 286:64-70.
39. Mancinella A., Mancinella M., Carpinteri G., Bellomo A., Fossati C., Gianturco V., et al. Is there a relationship between high C-reactive protein (CRP) levels and dementia?. Arch Gerontol Geriatr 2009, 49(Suppl 1):185-194.
40. O'Bryant S.E., Waring S.C., Hobson V., Hall J.R., Moore C.B., Bottiglieri T., et al. Decreased C-reactive protein levels in Alzheimer disease. J Geriatr Psychiatry Neurol 2010, 23:49-53.
41. Roberts R.O., Geda Y.E., Knopman D.S., Boeve B.F., Christianson T.J., Pankratz V.S., et al. Association of C-reactive protein with mild cognitive impairment. Alzheimers Dement 2009, 5:398-405.
42. Roberts R.O., Geda Y.E., Knopman D.S., Cha R.H., Boeve B.F., Ivnik R.J., et al. Metabolic syndrome, inflammation, and nonamnestic mild cognitive impairment in older persons: a population-based study. Alzheimer Dis Assoc Disord 2010, 24:11-18.
43. Kravitz B.A., Corrada M.M., Kawas C.H. Elevated C-reactive protein levels are associated with prevalent dementia in the oldest-old. Alzheimers Dement 2009, 5:318-323.
44. Davis G., Baboolal N., Nayak S., McRae A. Sialic acid, homocysteine and CRP: potential markers for dementia. Neurosci Lett 2009, 465:282-284.
45. Sundelof J., Kilander L., Helmersson J., Larsson A., Ronnemaa E., Degerman-Gunnarsson M., et al. Systemic inflammation and the risk of Alzheimer's disease and dementia: a prospective population-based study. J Alzheimers Dis 2009, 18:79-87.
46. Yano Y., Matsuda S., Hatakeyama K., Sato Y., Imamura T., Shimada K., et al. Plasma Pentraxin 3, but not high-sensitivity C-reactive protein, is a useful inflammatory biomarker for predicting cognitive impairment in elderly hypertensive patients. J Gerontol A Biol Sci Med Sci 2010, 65:547-552.
47. Erlinger T.P., Platz E.A., Rifai N., Helzlsouer K.J. C-reactive protein and the risk of incident colorectal cancer. JAMA 2004, 291:585-590.
48. Chaturvedi A.K., Caporaso N.E., Katki H.A., Wong H.L., Chatterjee N., Pine S.R., et al. C-reactive protein and risk of lung cancer. J Clin Oncol 2010.
49. Dos Santos Silva I., De Stavola B.L., Pizzi C., Meade T.W. Circulating levels of coagulation and inflammation markers and cancer risks: individual participant analysis of data from three long-term cohorts. Int J Epidemiol 2010.
50. Skipworth R.J., Moses A.G., Sangster K., Sturgeon C.M., Voss A.C., Fallon M.T., et al. Interaction of gonadal status with systemic inflammation and opioid use in determining nutritional status and prognosis in advanced pancreatic cancer. Support Care Cancer 2010.
51. Raghavendra V., Rutkowski M.D., DeLeo J.A. The role of spinal neuroimmune activation in morphine tolerance/hyperalgesia in neuropathic and sham-operated rats. J Neurosci 2002, 22:9980-9989.
52. Raghavendra V., Tanga F.Y., DeLeo J.A. Attenuation of morphine tolerance, withdrawal-induced hyperalgesia, and associated spinal inflammatory immune responses by propentofylline in rats. Neuropsychopharmacology 2004, 29:327-334.
53. Lawrence D.M., Thomas D.A., Wu D.Y. Glial cells and the neurobiology of addiction. ScientificWorldJournal 2007, 7:86-88.
54. Fellin T., D'Ascenzo M., Haydon P.G. Astrocytes control neuronal excitability in the nucleus accumbens. ScientificWorldJournal 2007, 7:89-97.
55. Adler M.W., Geller E.B., Chen X., Rogers T.J. Viewing chemokines as a third major system of communication in the brain. AAPS J 2005, 7:E865-E870.
56. Adler M.W., Rogers T.J. Are chemokines the third major system in the brain?. J Leukoc Biol 2005, 78:1204-1209.
57. White F., Wilson N. Opiate-induced hypernociception and chemokine receptors. Neuropharmacology 2010, 58:35-37.
58. Jin M.S., Kim S.E., Heo J.Y., Lee M.E., Kim H.M., Paik S.G., et al. Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide. Cell 2007, 130:1071-1082.
59. Kim H.M., Park B.S., Kim J.I., Kim S.E., Lee J., Oh S.C., et al. Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran. Cell 2007, 130:906-917.
60. Lee H.H., Kim H.S., Kang J.Y., Lee B.I., Ha J.Y., Yoon H.J., et al. Crystal structure of human nucleophosmin-core reveals plasticity of the pentamer-pentamer interface. Proteins 2007, 69:672-678.
61. Ohto U., Fukase K., Miyake K., Satow Y. Crystal structures of human MD-2 and its complex with antiendotoxic lipid IVa. Science 2007, 316:1632-1634.
62. Park Y.K., Choi S.B., Kim H., Kim K., Won B.H., Choi K., et al. Crystal structure and guest uptake of a mesoporous metal-organic framework containing cages of 3.9 and 4.7 nm in diameter. Angewandte Chemie (International ed.) 2007, 46:8230-8233.
63. Jin M.S., Lee J.O. Structures of the toll-like receptor family and its ligand complexes. Immunity 2008, 29:182-191.
64. Kang J.Y., Nan X., Jin M.S., Youn S.J., Ryu Y.H., Mah S., et al. Recognition of lipopeptide patterns by Toll-like receptor 2-Toll-like receptor 6 heterodimer. Immunity 2009, 31:873-884.
65. Alberts B., Johnson A., Lewis J., Raff M., Roberts K., Walter P., et al. Molecular biology of the cell 2008, Garland Science, New York. 2nd ed.
66. Hutchinson M.R., Zhang Y., Shridhar M., Evans J.H., Buchanan M.M., Zhao T.X., et al. Evidence that opioids may have toll-like receptor 4 and MD-2 effects. Brain Behav Immun 2010, 24:83-95.
67. Hutchinson M.R., Lewis S.S., Coats B.D., Skyba D.A., Crysdale N.Y., Berkelhammer D.L., et al. Reduction of opioid withdrawal and potentiation of acute opioid analgesia by systemic AV411 (ibudilast). Brain Behav Immun 2009, 23:240-250.
68. Bland S.T., Hutchinson M.R., Maier S.F., Watkins L.R., Johnson K.W. The glial activation inhibitor AV411 reduces morphine-induced nucleus accumbens dopamine release. Brain Behav Immun 2009.
69. Martinon F., Gaide O., Petrilli V., Mayor A., Tschopp J. NALP inflammasomes: a central role in innate immunity. Semin Immunopathol 2007, 29:213-229.
70. Martinon F., Mayor A., Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol 2009, 27:229-265.
71. Martinon F., Tschopp J. Inflammatory caspases: linking an intracellular innate immune system to autoinflammatory diseases. Cell 2004, 117:561-574.
72. Masters S.L., Simon A., Aksentijevich I., Kastner D.L. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*). Annu Rev Immunol 2009, 27:621-668.
73. Schroder K., Zhou R., Tschopp J. The NLRP3 inflammasome: a sensor for metabolic danger?. Science 2010, 327:296-300.
74. Schurr E., Gros P. A common genetic fingerprint in leprosy and Crohn's disease?. N Engl J Med 2009, 361:2666-2668.
75. Ting J.P., Duncan J.A., Lei Y. How the noninflammasome NLRs function in the innate immune system. Science 2010, 327:286-290.
76. de Calignon A., Fox L.M., Pitstick R., Carlson G.A., Bacskai B.J., Spires-Jones T.L., et al. Caspase activation precedes and leads to tangles. Nature 2010, 464:1201-1204.
77. Neri S., Bruno C.M., Pulvirenti D., Malaguarnera M., Italiano C., Mauceri B., et al. Randomized clinical trial to compare the effects of methadone and buprenorphine on the immune system in drug abusers. Psychopharmacology (Berl) 2005, 179:700-704.
78. Gamonal J., Acevedo A., Bascones A., Jorge O., Silva A. Levels of interleukin-1 beta, -8, and -10 and RANTES in gingival crevicular fluid and cell populations in adult periodontitis patients and the effect of periodontal treatment. J Periodontol 2000, 71:1535-1545.
79. Hser Y.I., Gelberg L., Hoffman V., Grella C.E., McCarthy W., Anglin M.D. Health conditions among aging narcotics addicts: medical examination results. J Behav Med 2004, 27:607-622.
80. Rosen D., Smith M.L., Reynolds C.F. The prevalence of mental and physical health disorders among older methadone patients. Am J Geriatr Psychiatry 2008, 16:488-497.
81. Arnsten J.H., Freeman R., Howard A.A., Floris-Moore M., Lo Y., Klein R.S. Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection. AIDS (London, England) 2007, 21:617-623.
82. Vestergaard P., Rejnmark L., Mosekilde L. Fracture risk associated with the use of morphine and opiates. J Intern Med 2006, 260:76-87.
83. Arnsten J.H., Freeman R., Howard A.A., Floris-Moore M., Santoro N., Schoenbaum E.E. HIV infection and bone mineral density in middle-aged women. Clin Infect Dis 2006, 42:1014-1020.
84. Kim T.W., Alford D.P., Malabanan A., Holick M.F., Samet J.H. Low bone density in patients receiving methadone maintenance treatment. Drug Alcohol Depend 2006, 85:258-262.
85. Reece A.S. Dental health in addiction. Aust Dent J 2009, 54:185-186.
86. Reece A.S. Dentition of addiction in Queensland: poor dental status and major contributing drugs. Aust Dent J 2007, 52:144-149.
87. Carter E.F. Dental implications of narcotic addiction. Aust Dent J 1978, 23:308-310.
88. Butler T., Osborne M., Barnard P.D. Oral health status of prison inmates - New South Wales, Australia. Aust Dental J 2003, 48:34-38.
89. Fan J., Hser Y.I., Herbeck D. Tooth retention, tooth loss and use of dental care among long-term narcotics abusers. Subst Abus 2006, 27:25-32.
90. Bailey M.T., Kinsey S.G., Padgett D.A., Sheridan J.F., Leblebicioglu B. Social stress enhances IL-1beta and TNF-alpha production by Porphyromonas gingivalis lipopolysaccharide-stimulated CD11b+ cells. Physiol Behav 2009, 98:351-358.
91. Gutierrez-Venegas G., Kawasaki-Cardenas P., Cruz-Arroyo S.R., Perez-Garzon M., Maldonado-Frias S. Actinobacillus actinomycetemcomitans lipopolysaccharide stimulates the phosphorylation of p44 and p42 MAP kinases through CD14 and TLR-4 receptor activation in human gingival fibroblasts. Life Sci 2006, 78:2577-2583.
92. Mark L.L., Haffajee A.D., Socransky S.S., Kent R.L., Guerrero D., Kornman K., et al. Effect of the interleukin-1 genotype on monocyte IL-1beta expression in subjects with adult periodontitis. J Periodontal Res 2000, 35:172-177.
93. Friedewald V.E., Kornman K.S., Beck J.D., Genco R., Goldfine A., Libby P., et al. The American Journal of Cardiology and Journal of Periodontology editors' consensus: periodontitis and atherosclerotic cardiovascular disease (diamond). J Periodontol 2009, 80:1021-1032.
94. Haraszthy V.I., Zambon J.J., Trevisan M., Zeid M., Genco R.J. Identification of periodontal pathogens in atheromatous plaques. J Periodontol 2000, 71:1554-1560.
95. Mattila K.J. Dental infections as a risk factor for acute myocardial infarction. Eur Heart J 1993, 14(Suppl K):51-53.
96. Nieto F.J. Infections and atherosclerosis: new clues from an old hypothesis?. Am J Epidemiol 1998, 148:937-948.
97. Schaefer A.S., Richter G.M., Groessner-Schreiber B., Noack B., Nothnagel M., El Mokhtari N.E., et al. Identification of a shared genetic susceptibility locus for coronary heart disease and periodontitis. PLoS Genet 2009, 5:e1000378.
98. Wu T., Trevisan M., Genco R.J., Dorn J.P., Falkner K.L., Sempos C.T. Periodontal disease and risk of cerebrovascular disease: the first national health and nutrition examination survey and its follow-up study. Arch Intern Med 2000, 160:2749-2755.
99. Wu T., Trevisan M., Genco R.J., Falkner K.L., Dorn J.P., Sempos C.T. Examination of the relation between periodontal health status and cardiovascular risk factors: serum total and high density lipoprotein cholesterol, C-reactive protein, and plasma fibrinogen. Am J Epidemiol 2000, 151:273-282.
100. Desvarieux M., Demmer R.T., Rundek T., Boden-Albala B., Jacobs D.R., Papapanou P.N., et al. Relationship between periodontal disease, tooth loss, and carotid artery plaque: the Oral Infections and Vascular Disease Epidemiology Study (INVEST). Stroke 2003, 34:2120-2125.
101. Ekhlassi S., Scruggs L.Y., Garza T., Montufar-Solis D., Moretti A.J., Klein J.R. Porphyromonas gingivalis lipopolysaccharide induces tumor necrosis factor-alpha and interleukin-6 secretion, and CCL25 gene expression, in mouse primary gingival cell lines: interleukin-6-driven activation of CCL2. J Periodontal Res 2008, 43:431-439.
102. Angelini F., Di Matteo G., Balestrero S., Brunetti E., Mancino G., Rossi P., et al. Nuclear factor kappaB activity is increased in peripheral blood mononuclear cells of children affected by atopic and non-atopic eczema. Int J Immunopathol Pharmacol 2007, 20:59-67.
103. Barnes N. Reducing inflammation in COPD: the evidence builds. Thorax 2007, 62:927-928.
104. Cosio M.G., Guerassimov A. Chronic obstructive pulmonary disease. Inflammation of small airways and lung parenchyma. Am J Respir Crit Care Med 1999, 160:S21-S25.
105. Decramer M., Rennard S., Troosters T., Mapel D.W., Giardino N., Mannino D., et al. COPD as a lung disease with systemic consequences - clinical impact, mechanisms, and potential for early intervention. COPD 2008, 5:235-256.
106. Garrod R., Ansley P., Canavan J., Jewell A. Exercise and the inflammatory response in chronic obstructive pulmonary disease (COPD) - does training confer anti-inflammatory properties in COPD?. Med Hypotheses 2007, 68:291-298.
107. Steingrimsson E., Copeland N.G., Jenkins N.A. Melanocyte stem cell maintenance and hair graying. Cell 2005, 121:9-12.
108. Reece A.S., Davidson P. Deficit of circulating stem - progenitor cells in opiate addiction: a pilot study. Subst Abus Treat Prev Policy 2007, 2:19-28.
109. Behmard S., Sadeghi A., Mohareri M.R., Kadivar R. Positive association of opium addiction and cancer of the bladder. Results of urine cytology in 3,500 opium addicts. Acta Cytol 1981, 25:142-146.
110. Fahmy M.S., Sadeghi A., Behmard S. Epidemiologic study of oral cancer in Fars Province, Iran. Community Dent Oral Epidemiol 1983, 11:50-58.
111. Ghavamzadeh A., Moussavi A., Jahani M., Rastegarpanah M., Iravani M. Esophageal cancer in Iran. Semin Oncol 2001, 28:153-157.
112. Mousavi M.R., Damghani M.A., Haghdoust A.A., Khamesipour A. Opium and risk of laryngeal cancer. Laryngoscope 2003, 113:1939-1943.
113. Sadeghi A., Behmard S. Cancer of the bladder in Southern Iran. Cancer 1978, 42:353-356.
114. Sadeghi A., Behmard S., Shafiepoor H., Zeighmani E. Cancer of the esophagus in southern Iran. Cancer 1977, 40:841-845.
115. Sadeghi A., Behmard S., Vesselinovitch S.D. Opium: a potential urinary bladder carcinogen in man. Cancer 1979, 43:2315-2321.
116. Weaver J.M., Dockery J.W., De la Puente J., Kevorkian A.Y., Hnat R.F. Narcotic addiction and cervical carcinoma. Acta Cytol 1966, 10:154-155.
117. Reece A. Lifetime prevalence of cervical neoplasia in addicted and medical patients. Aust N Z J Obstet Gynaecol 2007, 47:419-423.
118. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005, 352:1685-1695.
119. Kiechl S., Lorenz E., Reindl M., Wiedermann C.J., Oberhollenzer F., Bonora E., et al. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 2002, 347:185-192.
120. Kriszbacher I., Koppan M., Bodis J. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005, 353:429-430. author reply 429-430.
121. Thompson P.D., Buchner D., Pina I.L., Balady G.J., Williams M.A., Marcus B.H., et al. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity). Circulation 2003, 107:3109-3116.
122. Bauer S., Kerr B.J., Patterson P.H. The neuropoietic cytokine family in development, plasticity, disease and injury. Nat Rev Neurosci 2007, 8:221-232.
123. Bhat R., Steinman L. Innate and adaptive autoimmunity directed to the central nervous system. Neuron 2009, 64:123-132.
124. Boulanger L.M. Immune proteins in brain development and synaptic plasticity. Neuron 2009, 64:93-109.
125. Covacu R., Arvidsson L., Andersson A., Khademi M., Erlandsson-Harris H., Harris R.A., et al. TLR activation induces TNF-alpha production from adult neural stem/progenitor cells. J Immunol 2009, 182:6889-6895.
126. Deverman B.E., Patterson P.H. Cytokines and CNS development. Neuron 2009, 64:61-78.
127. Ekdahl C.T., Claasen J.H., Bonde S., Kokaia Z., Lindvall O. Inflammation is detrimental for neurogenesis in adult brain. Proc Natl Acad Sci USA 2003, 100:13632-13637.
128. Frost R.A., Nystrom G.J., Lang C.H. Lipopolysaccharide stimulates nitric oxide synthase-2 expression in murine skeletal muscle and C(2)C(12) myoblasts via Toll-like receptor-4 and c-Jun NH(2)-terminal kinase pathways. Am J Physiol Cell Physiol 2004, 287:C1605-C1615.
129. Hennighausen L., Robinson G.W. Signaling pathways in mammary gland development. Dev Cell 2001, 1:467-475.
130. Leonard W.J., O'Shea J.J. Jaks and STATs: biological implications. Annu Rev Immunol 1998, 16:293-322.
131. Rolls A., Shechter R., London A., Ziv Y., Ronen A., Levy R., et al. Toll-like receptors modulate adult hippocampal neurogenesis. Nat Cell Biol 2007, 9:1081-1088.
132. Franceschi C., Monti D., Sansoni P., Cossarizza A. The immunology of exceptional individuals: the lesson of centenarians. Immunol Today 1995, 16:12-16.
133. Sansoni P., Cossarizza A., Brianti V., Fagnoni F., Snelli G., Monti D., et al. Lymphocyte subsets and natural killer cell activity in healthy old people and centenarians. Blood 1993, 82:2767-2773.
134. Wikby A., Ferguson F., Forsey R., Thompson J., Strindhall J., Lofgren S., et al. An immune risk phenotype, cognitive impairment, and survival in very late life: impact of allostatic load in Swedish octogenarian and nonagenarian humans. J Gerontol A Biol Sci Med Sci 2005, 60:556-565.
135. Chien K.R., Karsenty G. Longevity and lineages: toward the integrative biology of degenerative diseases in heart, muscle, and bone. Cell 2005, 120:533-544.
136. Herbig U., Ferreira M., Condel L., Carey D., Sedivy J.M. Cellular senescence in aging primates. Science 2006, 311:1257.
137. Kirkwood T.B. Understanding the odd science of aging. Cell 2005, 120:437-447.
138. Eisch A.J., Mandyam C.D. Drug dependence and addiction. II: Adult neurogenesis and drug abuse. Am J Psychiatry 2004, 161:426.
139. Lasky D.I., Zagon I.S., McLaughlin P.J. Effect of maternally administered heroin on the motor activity of rat offspring. Pharmacol Biochem Behav 1977, 7:281-284.
140. Zagon I.S., McLaughlin P.J. Methadone and brain development. Experientia 1977, 33:1486-1487.
141. Zagon I.S., McLaughlin P.J. The effects of different schedules of methadone treatment on rat brain development. Exp Neurol 1977, 56:538-552.
142. Zagon I.S., McLaughlin P.J. Effects of chronic morphine administration on pregnant rats and their offspring. Pharmacology 1977, 15:302-310.
143. Zagon I.S., McLaughlin P.J. Morphine and brain growth retardation in the rat. Pharmacology 1977, 15:276-282.
144. Zagon I.S., Verderame M.F., McLaughlin P.J. The biology of the opioid growth factor receptor (OGFr). Brain Res 2002, 38:351-376.
145. Cheng F., McLaughlin P.J., Verderame M.F., Zagon I.S. The OGF-OGFr axis utilizes the p16INK4a and p21WAF1/CIP1 pathways to restrict normal cell proliferation. Mol Biol Cell 2009, 20:319-327.
146. Carpentier P.A., Palmer T.D. Immune influence on adult neural stem cell regulation and function. Neuron 2009, 64:79-92.
147. Eisch A.J., Barrot M., Schad C.A., Self D.W., Nestler E.J. Opiates inhibit neurogenesis in the adult rat hippocampus. Proc Natl Acad Sci USA 2000, 97:7579-7584.
148. Eisch A.J. Adult neurogenesis: implications for psychiatry. Prog Brain Res 2002, 138:315-342.
149. Nestler E.J., Barrot M., DiLeone R.J., Eisch A.J., Gold S.J., Monteggia L.M. Neurobiology of depression. Neuron 2002, 34:13-25.
150. Mao J., Sung B., Ji R.R., Lim G. Neuronal apoptosis associated with morphine tolerance. evidence for an opioid-induced neurotoxic mechanism. J Neurosci 2002, 22:7650-7661.
151. Salvemini D., Neumann W.L. Peroxynitrite: a strategic linchpin of opioid analgesic tolerance. Trends Pharmacol Sci 2009, 30:194-202.
152. Svensson A.L., Bucht N., Hallberg M., Nyberg F. Reversal of opiate-induced apoptosis by human recombinant growth hormone in murine foetus primary hippocampal neuronal cell cultures. Proc Natl Acad Sci USA 2008, 105:7304-7308.
153. Campisi J. Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell 2005, 120:513-522.
154. Lombard D.B., Chua K.F., Mostoslavsky R., Franco S., Gostissa M., Alt F.W. DNA repair, genome stability, and aging. Cell 2005, 120:497-512.
155. Ceriello A., Giugliano D., Passariello N., Quatraro A., Dello Russo P., Torella R., et al. Impaired glucose metabolism in heroin and methadone users. Horm Metab Res 1987, 19:430-433.
156. Ceriello A., Quatraro A., Giugliano D. Opiate addict as diabetic patient?. Diabetes Care 1988, 11:443.
157. Passariello N., Giugliano D., Ceriello A., Chiariello A., Sgambato S., D'Onofrio F. Impaired insulin response to glucose but not to arginine in heroin addicts. J Endocrinol Invest 1986, 9:353-357.
158. Passariello N., Giugliano D., Quatraro A., Consoli G., Sgambato S., Torella R., et al. Glucose tolerance and hormonal responses in heroin addicts. A possible role for endogenous opiates in the pathogenesis of non-insulin-dependent diabetes. Metabolism 1983, 32:1163-1165.
159. Gosnell B.A., Levine A.S. Reward systems and food intake: role of opioids. Intl J Obes (2005) 2009, 33(Suppl. 2):S54-S58.
160. Olszewski P.K., Wirth M.M., Grace M.K., Levine A.S., Giraudo S.Q. Evidence of interactions between melanocortin and opioid systems in regulation of feeding. NeuroReport 2001, 12:1727-1730.
161. Zheng H., Patterson L.M., Berthoud H.R. Orexin signaling in the ventral tegmental area is required for high-fat appetite induced by opioid stimulation of the nucleus accumbens. J Neurosci 2007, 27:11075-11082.
162. Kolarzyk E., Pach D., Wojtowicz B., Szpanowska-Wohn A., Szurkowska M. Nutritional status of the opiate dependent persons after 4 years of methadone maintenance treatment. Przegl Lek 2005, 62:373-377.
163. Singhal P.C., Bhaskaran M., Patel J., Patel K., Kasinath B.S., Duraisamy S., et al. Role of p38 mitogen-activated protein kinase phosphorylation and Fas-Fas ligand interaction in morphine-induced macrophage apoptosis. J Immunol 2002, 168:4025-4033.
164. Singhal P., Kapasi A., Reddy K., Franki N. Opiates Promote T Cell Apoptosis through JNK and Caspase Pathway. Drugs of Abuse and Infectious Diseases 2001, vol. 1:127-135. Kluwer Academic/Plenum Publishers. H. Friedman (Ed.).
165. Yin D., Woodruff M., Zhang Y., Whaley S., Miao J., Ferslew K., et al. Morphine promotes Jurkat cell apoptosis through pro-apoptotic FADD/P53 and anti-apoptotic PI3K/Akt/NF-kappaB pathways. J Neuroimmunol 2006, 174:101-107.
166. Chao C.C., Hu S., Molitor T.W., Zhou Y., Murtaugh M.P., Tsang M., et al. Morphine potentiates transforming growth factor-beta release from human peripheral blood mononuclear cell cultures. J Pharmacol Exp Ther 1992, 262:19-24.
167. Singhal P.C., Kapasi A.A., Franki N., Reddy K. Morphine-induced macrophage apoptosis: the role of transforming growth factor-beta. Immunology 2000, 100:57-62.
168. Dozio E., Ruscica M., Galliera E., Corsi M.M., Magni P. Leptin, ciliary neurotrophic factor, leukemia inhibitory factor and interleukin-6: class-I cytokines involved in the neuroendocrine regulation of the reproductive function. Curr Protein Pept Sci 2009, 10:577-584.
169. Melmed S. Gp130-Related cytokines and their receptors in the pituitary. Trends Endocrinol Metab 1997, 8:391-397.
170. Shimon I., Yan X., Ray D.W., Melmed S. Cytokine-dependent gp130 receptor subunit regulates human fetal pituitary adrenocorticotropin hormone and growth hormone secretion. J Clin Invest 1997, 100:357-363.
171. Collado M., Blasco M.A., Serrano M. Cellular senescence in cancer and aging. Cell 2007, 130:223-233.
172. Flores I., Canela A., Vera E., Tejera A., Cotsarelis G., Blasco M.A. The longest telomeres: a general signature of adult stem cell compartments. Genes Dev 2008, 22:654-667.